Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder

Estimated reading time: 1 minutes

• About The Author

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary hemorrhagic telangiectasia (HHT), the world’s second-most-common inherited bleeding disorder, affects approximately 1-in-5,000 people and can have life-threatening complications, but there are currently no U.S. FDA-approved drugs to treat HHT.

About The Author

See author's posts

Trending

Android malware steals payment card data using previously unseen technique